Latest Headlines

  1. Galmed Pharmaceuticals Launches VCU Collaboration To Tackle Drug Resistance In GI Cancers 4/17/2025

    Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company, today announced a sponsored research collaboration with Virginia Commonwealth University (VCU) to investigate Aramchol's potential in overcoming drug resistance in gastrointestinal (GI) cancers.

  2. Aptar Announces Clinical Validation Study To Accelerate US FDA Approval Of SmartTrack™ In-Vitro-in-Silico Platform For Pressurized Metered-Dose Inhalers 4/16/2025

    AptarGroup, Inc., a global leader in drug and consumer product dosing, dispensing and protection technologies, today announces the commencement of a clinical study to validate its proprietary SmartTrack platform.

  3. Lisata Therapeutics Announces Research License With Catalent 4/15/2025

    Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a clinical-stage pharmaceutical company developing innovative therapies for the treatment of advanced solid tumors and other serious diseases, today announced that the Company has entered into a research license with Catalent, Inc. (“Catalent”) to evaluate, in a preclinical setting, the efficacy of Lisata's iRGD cyclic peptide product candidate, certepetide, as a payload used in the context of Catalent’s SMARTag® antibody-drug conjugate (“ADC”) dual-payload technology platform for the treatment of difficult-to-treat-diseases, including advanced solid tumors.

  4. Scilex Holding Company Announces Approval Of A New Drug Submission (NDS) From The Health Canada's Pharmaceutical Drugs Directorate, Bureau Of Cardiology, Allergy And Neurological Sciences For ELYXYB Acute Treatment Migraine With Or Without Aura In Canada 4/15/2025

    Scilex Holding Company (Nasdaq: SCLX, “Scilex” or “Company”), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain and, following the formation of its proposed joint venture with IPMC Company, neurodegenerative and cardiometabolic disease, today announced that it has received approval of a New Drug Submission (NDS) from the Health Canada’s Pharmaceutical Drugs Directorate, Bureau of Cardiology, Allergy and Neurological Sciences for ELYXYB®’s acute treatment of migraine with or without aura in Canada.

  5. Predictive Oncology Develops Novel Approach To Identifying Clinically Viable Abandoned Drugs 4/15/2025

    Predictive Oncology Inc. (NASDAQ: POAI), a leader in AI-driven drug discovery, announced today that it has made significant progress along the continuum of biomarker discovery, drug discovery and drug repurposing.

  6. Elix And PRISM BioLab Join Forces To Accelerate AI-Driven Drug Discovery For Challenging Protein-Protein Interaction Targets 4/15/2025

    Elix, Inc. (CEO: Shinya Yuki / HQ: Tokyo, hereinafter “Elix”), an AI drug discovery company with the mission of “Rethinking Drug Discovery”, today announced that it has entered into a drug discovery collaboration with PRISM BioLab, Co. Ltd. (CEO: Dai Takehara / HQ: Kanagawa, hereinafter "PRISM BioLab"), effective April 1, 2025.

  7. eGenesis And OrganOx Announce U.S. FDA Clearance Of IND Application For The Treatment Of Patients With Acute-On-Chronic Liver Failure 4/15/2025

    eGenesis, a biotechnology company developing human-compatible engineered organs to treat patients suffering from organ failure, and OrganOx Ltd., a leading organ medical technology company, today announced the U.S. Food & Drug Administration (FDA) has cleared the investigational new drug (IND) application for EGEN-5784, a human-compatible, genetically engineered porcine liver, used in combination with the OrganOx extracorporeal liver cross-circulation (ELC) system, for patients with acute-on-chronic liver failure (ACLF) suffering from decompensated liver function in the intensive care setting.

  8. Certara Launches Non-Animal Navigator™ Solution To Help Drug Developers Reduce Reliance On Animal Testing 4/14/2025

    Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced the launch of its Non-Animal Navigator™ solution designed to help biopharmaceutical companies lead the transition ignited by the FDA’s Roadmap to Reducing Animal Testing in Preclinical Safety Studies.

  9. ProBio To Present Data On Its CD3 Agonistic Single Domain Antibody Platform For Accelerated Development Of T Cell Engager Multi-Specific Antibodies 4/14/2025

    ProBio, a global leader in the antibody discovery and development, is pleased to announce its upcoming poster presentation at the American Association for Cancer Research® (AACR) 116th Annual Meeting, to be held April 25 to 30, 2025, at the McCormick Place Convention Center in Chicago, Illinois.

  10. Researchers Resurrect Extinct Gene In Plants With Major Implications For Drug Development 4/14/2025

    Northeastern University researchers resurrected an extinct plant gene, turning back the evolutionary clock to pave a path forward for the development and discovery of new drugs.